Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11208053 | 0.88 | CYP1A2 (0.33) | CYP1A2MAPK1MEN1KMT2ATSHR | |
| SCHEMBL17782036 | 0.83 | LMNA (0.47) | CYP1A2MAPK1MEN1KMT2ACA12 | |
| SCHEMBL15015968 | 0.83 | CYP1A2 (0.43) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL15015862 | 0.83 | CYP1A2 (0.43) | CYP1A2MAPK1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL17782046 | 0.81 | LMNA (0.53) | CYP1A2MAPK1MEN1KMT2ACA12 | |
| SCHEMBL10706034 | 0.80 | ALDH1A1 (0.42) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL11078810 | 0.80 | ALDH1A1 (0.37) | CYP1A2MAPK1MEN1KMT2ATSHR | |
| SCHEMBL16334777 | 0.78 | BACE1 (0.43) | — | |
| SCHEMBL14577017 | 0.78 | LMNA (0.47) | CYP1A2MAPK1MEN1KMT2ACA12 | |
| SCHEMBL13509940 | 0.78 | LMNA (0.41) | CYP1A2MAPK1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013824-B1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2012120544-A2 | PROCESS FOR N-[2-n-BUTYL-3-[4-[3-(DI-n-BUTYLAMINO) PROPOXY]ENZOYL]BENZOFURAN-5-YL]METHANESULFONAMIDE HYDROCHLORIDE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2012-09-13 | — | — | WO | disclosed |
| US-5089529-A | Antiarrhythmia agents | NIPPON SHINYAKU CO., LTD. (JP) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | CYP1A2 1516/4885MAPK1 2233/4885MEN1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.